How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings data on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to analyst estimates of $25.07 million.

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com . Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , ACADIA Pharmaceuticals (ACAD) , Sangamo Therapeutics (SGMO) , Dynavax Technologies (DVAX) , TG Therapeutics (TGTX) , VBI Vaccines (VBIV) , Exelixis (EXEL) and Nabriva Therapeutics (NBRV) .

NASDAQ:ADMS

Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free ADMS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $8.22
▼
$8.22
50-Day Range: $7.97
▼
$8.23
52-Week Range: $4.02
▼
$9.15

Volume: N/A
Average Volume: 692,487 shs
Market Capitalization: $376.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Adamas Pharmaceuticals alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

Find out more here >>>

ADMS Stock News Headlines

April 7, 2023 | benzinga.com

Survalent, Electroval win bid to provide ICE "first of its kind" ADMS and DERMS platform

April 7, 2023 | marketwatch.com

Advanced Distribution Management Systems (ADMS) Market 2023 | Global Industry Report Forecast 2029

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 30, 2023 | marketwatch.com

Advanced Distribution Management Systems (ADMS) Market LATEST REPORT 2023 to 2030

March 3, 2023 | investing.com

Adamas One Corp (JEWL)

March 1, 2023 | marketwatch.com

2023 Advanced Distribution Management System (ADMS) Market: Top Growing Regions for Business Leaders by 2029

March 1, 2023 | marketwatch.com

Advanced Distribution Management System (ADMS) Market 2023 | Global Industry Report Forecast 2029

February 24, 2023 | marketwatch.com

Advanced Distributed Management System (ADMS) Market Is Booming Worldwide Forecast 2023-2029

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

January 14, 2023 | marketwatch.com

Advanced Distribution Management Systems (ADMS) Market Future Trends Demand 2023, and Forecast to 2029

May 25, 2022 | insidermonkey.com

8 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital

November 24, 2021 | finance.yahoo.com

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

November 4, 2021 | finance.yahoo.com

Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call Transcript

November 2, 2021 | finance.yahoo.com

How Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?

November 1, 2021 | bizjournals.com

East Bay drug maker's potential sale brings lawsuits, job cuts

October 28, 2021 | finance.yahoo.com

Will Adamas Pharmaceuticals (ADMS) Report Negative Q3 Earnings? What You Should Know

October 27, 2021 | finance.yahoo.com

ADAMAS ALERT: Bragar Eagel & Squire, P.C. Announces Commencement of Tender Offer and Encourages Investors to Contact the Firm

October 21, 2021 | finance.yahoo.com

Why Supernus' Acquisition of Adamas Is a Smart Move

October 18, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

October 18, 2021 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, AZPN, GSKY, GWB; Shareholders are Encouraged to Contact the Firm

October 16, 2021 | prnewswire.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS

October 15, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS

October 14, 2021 | finance.yahoo.com

ADAMAS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ADMS and Encourages Investors to Contact the Firm

October 13, 2021 | businesswire.com

ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas ...

October 12, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Adamas Pharmaceuticals, Inc. Merger

October 12, 2021 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, AZPN, CXP; Shareholders are Encouraged to Contact the Firm

October 11, 2021 | businesswire.com

Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to ...

See More Headlines

Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ADMS
CUSIP: N/A
CIK: 1328143
Web: www.adamaspharma.com
Phone: (510) 450-3500
Fax: 510-428-0519
Employees: 138
Year Founded: 2002

Profitability

EPS (Most Recent Fiscal Year): ($1.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-57,400,000.00
Net Margins: -71.11%
Pretax Margin: -71.11%
Return on Equity: N/A
Return on Assets: -42.96%

Debt

Debt-to-Equity Ratio: 21.25
Current Ratio: 4.53
Quick Ratio: 4.17

Sales & Book Value

Annual Sales: $74.46 million
Price / Sales: 5.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.47) per share
Price / Book: -17.49

Miscellaneous

Outstanding Shares: 45,787,000
Free Float: 37,133,000
Market Cap: $376.37 million
Optionable: Optionable
Beta: 2.82

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Neil F. McFarlane
Chief Executive Officer & Director
Christopher B. Prentiss
Chief Financial Officer
Adrian Quartel
Chief Medical Officer
Vijay Shreedhar
Chief Commercial Officer
Jill M. Jene
Head-Corporate Development & Strategy

Key Competitors

View All Competitors

ADMS Stock Analysis - Frequently Asked Questions

How were Adamas Pharmaceuticals' earnings last quarter?: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings data on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to analyst estimates of $25.07 million.
What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?: 2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Adamas Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

This page (NASDAQ:ADMS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis

About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)

ADMS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

ADMS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info